Brief: BIORETEC says CEO Alan Donze To Resign Effective July 7, 2025
15/05/2025 06:07
May 15 (Reuters) - Bioretec Oy BRETEC.HE: BIORETEC LTD'S BUSINESS REVIEW Q1 2025: STRONG NET SALES IN THE FIRST QUARTER; CE APPROVAL WITH COMPREHENSIVE INDICATIONS RECEIVED IN JANUARY ACCELERATES THE FUTURE EXPANSION OF REMEOS PRODUCTS Source text: ID:nWkr54m53j Further company coverage: BRETEC.HE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioretec Oy
See all newsBrief: Bioretec Initiates Change Negotiations
Brief: Bioretec Gets Marketing Authorization From FDA
Brief: Bioretec Receives FDA 510(K) Clearance For Its Activascrew Cannulated Com Bioabsorbable Compression Screw
Finland's Bioretec H1 revenue rises 12%, loss narrows
Brief: Bioretec Q2 Net Sales EUR 1.1 Million